Sorrento Therapeutics, Inc.
SRNE
$0.001
-$0.0031-75.61%
OTC PK
| 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | |
|---|---|---|---|---|---|
| Revenue | 16.89% | 6.44% | 18.78% | 17.51% | 7.76% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 16.89% | 6.44% | 18.78% | 17.51% | 7.76% |
| Cost of Revenue | -7.23% | -3.42% | 15.90% | 35.07% | 35.70% |
| Gross Profit | 14.43% | 6.45% | -14.99% | -41.38% | -47.09% |
| SG&A Expenses | -1.07% | -2.55% | -7.50% | 7.62% | 22.96% |
| Depreciation & Amortization | 9.89% | 6.74% | 4.47% | 2.20% | -1.68% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -4.32% | -2.94% | 4.84% | 21.53% | 29.27% |
| Operating Income | 7.36% | 4.32% | -2.84% | -22.16% | -33.07% |
| Income Before Tax | -2.60% | -35.78% | -25.40% | -47.88% | -71.33% |
| Income Tax Expenses | 128.86% | 123.83% | 92.79% | -7,819.29% | -4,743.24% |
| Earnings from Continuing Operations | -10.67% | -46.55% | -34.63% | -38.64% | -61.74% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 2,937.50% | 4,428.92% | 504.43% | -2.81% | -77.90% |
| Net Income | -4.64% | -42.40% | -33.74% | -38.87% | -63.88% |
| EBIT | 7.36% | 4.32% | -2.84% | -22.16% | -33.07% |
| EBITDA | 7.88% | 4.66% | -2.72% | -22.69% | -33.88% |
| EPS Basic | 28.86% | 6.60% | 7.61% | -7.89% | -31.29% |
| Normalized Basic EPS | 43.48% | 37.72% | 26.23% | 6.87% | -11.83% |
| EPS Diluted | 28.44% | 6.18% | 7.36% | -8.03% | -31.29% |
| Normalized Diluted EPS | 43.48% | 37.72% | 25.29% | 5.58% | -14.10% |
| Average Basic Shares Outstanding | 50.61% | 52.34% | 42.17% | 31.86% | 23.69% |
| Average Diluted Shares Outstanding | 50.61% | 52.34% | 40.11% | 29.88% | 21.05% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |